Purpose

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Inclusion Criteria for Enrollment Phase

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Histological or cytological diagnosis of Stage IB (tumors greater than or equal to [>/=] 4 centimeters [cm])-IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) NSCLC (per the Union Internationale Contre le Cancer staging system (UICC)/American Joint Committee on Cancer staging system (AJCC) staging system, 7th edition; Detterbeck et al. 2009)

- Participants must have had complete resection of NSCLC 4-12 weeks (>/=28 days and less than or equal to [</=] 84 days) prior to enrollment and must be adequately recovered from surgery

- If mediastinoscopy was not performed preoperatively, it is required that, at a minimum, mediastinal lymph node systematic sampling will have occurred. Systematic sampling is defined as removal of at least one representative lymph node at specified levels. MLND entails resection of all lymph nodes at those same levels. For a right thoracotomy, sampling or MLND is required at levels 4 and 7 and for a left thoracotomy, levels 5 and/or 6 and 7. Exceptions will be granted if there is clear documentation in the operative report or in a separately submitted addendum by the surgeon of exploration of the required lymph node areas, the participant will be considered eligible if no lymph nodes are found in those areas; if participants have documented N2 disease in one level (per the UICC/AJCC staging system, 7th edition; Detterbeck et al. 2009), not all levels need to be sampled; if the preoperative staging imaging results (contrast computed tomography [CT] and positron emission tomography [PET] scans) do not suggest evidence of disease in the mediastinum, the participant will be considered eligible if N2 nodal sampling is not performed per surgeon's decision

- Eligible to receive a cisplatin-based chemotherapy regimen

- Adequate hematologic and end-organ function

- Women who are not postmenopausal (>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of cisplatin-based chemotherapy

Inclusion Criteria for Randomized Phase - Women who are not postmenopausal (>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of atezolizumab or BSC

Exclusion Criteria

Exclusion Criteria for Enrollment Phase

- Illness or condition that may interfere with a participant's capacity to understand, follow, and/or comply with study procedures

- Pregnant and lactating women

- Treatment with prior systemic chemotherapy: Chemotherapy for early stage of malignancy with curative intent, provided that the last dose received was more than 5 years prior to enrollment and low-dose chemotherapy for non-malignant conditions may be allowed upon approval by the Medical Monitor

- Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years before enrollment

- Treatment with any other investigational agent with therapeutic intent within 28 days prior to enrollment

- Participants with hearing impairment

- Known sensitivity to any component of the chemotherapy regimen the participant will be assigned to, or to mannitol

- Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti programmed death ligand 1 (PD-L1) therapeutic antibodies

- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS greater than [>] 90 percent [%]) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

- Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation

- History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis

- Positive test for human immunodeficiency virus (HIV)

- Participants with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C

- Active tuberculosis

- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within the previous 3 months, unstable arrhythmias, or unstable angina

- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan

- Prior allogeneic bone marrow transplantation or solid organ transplant

- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications

- Known tumor PD-L1 expression status as determined by an immunohistochemistry (IHC) assay from other clinical studies (e.g., participants whose PD-L1 expression status was determined during screening for entry into a study with anti-PD-1 or anti-PD-L1 antibodies but were not eligible are excluded)

Specific Exclusions for Pemetrexed Treatment

- Participants with squamous cell histology

Exclusion Criteria for Randomized Phase

- Signs or symptoms of infection within 14 days prior to randomization (severe infection within 28 days prior to randomization), including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia

- Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to randomization

- Major surgical procedure within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study

- Administration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such a live attenuated vaccine will be required during the study

- Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to randomization: Prior treatment with cancer vaccines is allowed

- Treatment with systemic corticosteroids or other immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Atezolizumab
Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
  • Drug: Atezolizumab
    Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
    Other names:
    • MPDL3280A; TECENTRIQ
  • Drug: Cisplatin
    Participants will receive cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of each of the four 21-day cycles.
  • Drug: Vinorelbine
    Participants will receive vinorelbine 30 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
  • Drug: Docetaxel
    Participants will receive docetaxel 75 mg/m^2 IV on Day 1 of each of the four 21-day cycles.
  • Drug: Gemcitabine
    Participants will receive gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
  • Drug: Pemetrexed
    Participants will receive pemetrexed 500 mg/m^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Active Comparator
Best Supportive Care
Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
  • Drug: Cisplatin
    Participants will receive cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of each of the four 21-day cycles.
  • Drug: Vinorelbine
    Participants will receive vinorelbine 30 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
  • Drug: Docetaxel
    Participants will receive docetaxel 75 mg/m^2 IV on Day 1 of each of the four 21-day cycles.
  • Drug: Gemcitabine
    Participants will receive gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
  • Drug: Pemetrexed
    Participants will receive pemetrexed 500 mg/m^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.

Recruiting Locations

Highlands Oncology Group
Rogers, Arkansas 72758

Southern California Permanente Medical Group Bellflower
Bellflower, California 90706

Compassionate Cancer Care Medical Group, Inc
Corona, California 92882

California Cancer Associates for Research & Excellence, Inc.
Encinitas, California 92008

Cedars Sinai Medical Center
Los Angeles, California 90048

Kaiser Permanente Oakland Medical Center
Oakland, California 94611

Stanford University
Palo Alto, California 94305

Kaiser Permanente Medical Center - Roseville
Roseville, California 95661

Kaiser Permanente - Sacramento Medical Center and Medical Offices
Sacramento, California 95825

Kaiser Permanente - San Francisco Medical Center
San Francisco, California 94115

Kaiser Permanente - San Jose Medical Center
San Jose, California 95119

Kaiser Permanente - San Leandro Medical Center
San Leandro, California 94577

Kaiser Permanente - Santa Clara
Santa Clara, California 95051

Kaiser Permanente - South San Francisco
South San Francisco, California 94080

Kaiser Permanente; Oncology Clinical Trials
Vallejo, California 94589

Kaiser Permanente - Walnut Creek
Walnut Creek, California 94596

Eastern Connecticut Hematology and Oncology Associates; (ECHO)
Norwich, Connecticut 06360

Lynn Cancer Institute - West
Boca Raton, Florida 33428

University of Miami School of Medicine - Sylvester at Deerfield
Deerfield Beach, Florida Suite 200

Holy Cross Hospital Inc
Fort Lauderdale, Florida 33308

Florida Cancer Specialists-Broadway, Fort Myers
Fort Myers, Florida 33908

SCRI Florida Cancer Specialists North; Research Office North Region.
Saint Petersburg, Florida 33705

SCRI Florida Cancer Specialists East
Tallahassee, Florida 32308

University Cancer & Blood Center, LLC
Athens, Georgia 30607

Northwest Georgia Oncology Centers P.C.
Carrollton, Georgia 30117

Central Georgia Cancer Care PC
Macon, Georgia 31201

Lewis Hall Singletary Oncology Center
Thomasville, Georgia 31792

Rush University Medical Center
Chicago, Illinois 60612

University of Illinois at Chicago
Chicago, Illinois 60612

Ingalls Memorial Hospital
Harvey, Illinois 60426

Oncology Specialists, S.C.
Park Ridge, Illinois 60068

Illinois Cancer Care
Peoria, Illinois 61615

Quincy Medical Group; Canc Ctr at Blessing Hosp
Quincy, Illinois 62301

Southern Illinois University, Simmons Cancer Institute
Springfield, Illinois 62794

New England Cancer Specialists
Scarborough, Maine 04074

VA Boston Healthcare System; Hematology and Oncology
Boston, Massachusetts 2130

Karmanos Cancer Institute
Detroit, Michigan 48201

Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan 49503

Hematology and Oncology Associates at Bridgepoint
Tupelo, Mississippi 38801

St. Luke's Cancer Institute
Kansas City, Missouri 64111

Comprehensive Cancer Centers of Nevada
Henderson, Nevada 89014

Saint Barnabas Medical Center
Livingston, New Jersey 07039

Morristown Medical Center
Morristown, New Jersey 07962

Valley Hospital; Oncology Research
Paramus, New Jersey 07652

Regional Cancer Care Associates LLC
Sewell, New Jersey 08080

Overlook Medical Center; Medical Diagnostic Associates
Summit, New Jersey 07901

Clinical Research Alliance
Lake Success, New York 11042

Weill Cornell Medical College
New York, New York 10065

Presbyterian Hospital
Charlotte, North Carolina 28204

W.G. Bill Hefner VA Medical Center
Salisbury, North Carolina

University of Cincinnati
Cincinnati, Ohio 45203-0542

Mark H. Zangmeister Center
Columbus, Ohio 43219

Oregon Health and Science University
Portland, Oregon 97239

Pinnacle Health
Harrisburg, Pennsylvania 17110

Allegheny General Hospital
Pittsburgh, Pennsylvania 15212

Rhode Island Hospital
Providence, Rhode Island 02903

Greenville Health System
Greenville, South Carolina 29605

University Oncology Associates
Chattanooga, Tennessee 37403

SCRI Tennessee Oncology Chattanooga
Chattanooga, Tennessee 37404

Sarah Cannon Cancer Center
Germantown, Tennessee 38138

SCRI The Center For Cancer and Blood Disorders
Denton, Texas 76210

Houston Methodist Cancer Center
Houston, Texas 77030

Wellmont Medical Associates
Bristol, Virginia 24201

Hematology Oncology Associates of Fredericksburg, Inc.
Fredericksburg, Virginia 22408

MultiCare Regional Cancer Center - Auburn
Auburn, Washington 98002-4117

Providence Everett Med Ctr
Everett, Washington 98201

VA Puget Sound Health Care Sys
Seattle, Washington 98108

Swedish Medical Center
Seattle, Washington 98122

More Details

NCT ID
NCT02486718
Status
Recruiting
Sponsor
Hoffmann-La Roche

Study Contact

Reference Study ID Number: GO29527 www.roche.com/about_roche/roche_worldwide.htm
888-662-6728 (U.S. and Canada)
global-roche-genentech-trials@gene.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.